Trial Profile
A randomized, double-blind, two-treatment, single-period, parallel design study to compare the pharmacokinetics and pharmacodynamics (PK/PD) of R-TPR-029 (test pegfilgrastim) 6 mg/0.6 mL of Reliance Life Sciences Pvt. Ltd., India with Neulasta (reference pegfilgrastim) of Amgen Europe BV, the Netherlands in healthy, adult, human subjects following subcutaneous administration under fasting condition.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Reliance Life Sciences
- 09 Sep 2016 New trial record